248 related articles for article (PubMed ID: 21291269)
21. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes.
Sarcevic B; Lilischkis R; Sutherland RL
J Biol Chem; 1997 Dec; 272(52):33327-37. PubMed ID: 9407125
[TBL] [Abstract][Full Text] [Related]
22. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate.
Davies TG; Tunnah P; Meijer L; Marko D; Eisenbrand G; Endicott JA; Noble ME
Structure; 2001 May; 9(5):389-97. PubMed ID: 11377199
[TBL] [Abstract][Full Text] [Related]
23. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
[TBL] [Abstract][Full Text] [Related]
24. Biochemical characterization of Cdk2-Speedy/Ringo A2.
Cheng A; Gerry S; Kaldis P; Solomon MJ
BMC Biochem; 2005 Sep; 6():19. PubMed ID: 16191191
[TBL] [Abstract][Full Text] [Related]
25. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.
Brown NR; Noble ME; Endicott JA; Johnson LN
Nat Cell Biol; 1999 Nov; 1(7):438-43. PubMed ID: 10559988
[TBL] [Abstract][Full Text] [Related]
26. Break CDK2/Cyclin E1 interface allosterically with small peptides.
Chen H; Zhao Y; Li H; Zhang D; Huang Y; Shen Q; Van Duyne R; Kashanchi F; Zeng C; Liu S
PLoS One; 2014; 9(10):e109154. PubMed ID: 25290691
[TBL] [Abstract][Full Text] [Related]
27. Structural prediction of the interaction of the tumor suppressor p27
Li J; Vervoorts J; Carloni P; Rossetti G; Lüscher B
BMC Bioinformatics; 2017 Jan; 18(1):15. PubMed ID: 28056778
[TBL] [Abstract][Full Text] [Related]
28. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A.
Schulman BA; Lindstrom DL; Harlow E
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10453-8. PubMed ID: 9724724
[TBL] [Abstract][Full Text] [Related]
29. The crystal structure of cyclin A.
Brown NR; Noble ME; Endicott JA; Garman EF; Wakatsuki S; Mitchell E; Rasmussen B; Hunt T; Johnson LN
Structure; 1995 Nov; 3(11):1235-47. PubMed ID: 8591034
[TBL] [Abstract][Full Text] [Related]
30. Targeting Conformational Activation of CDK2 Kinase.
Pellerano M; Tcherniuk S; Perals C; Ngoc Van TN; Garcin E; Mahuteau-Betzer F; Teulade-Fichou MP; Morris MC
Biotechnol J; 2017 Aug; 12(8):. PubMed ID: 28430399
[TBL] [Abstract][Full Text] [Related]
31. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
32. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
33. A novel binding pocket of cyclin-dependent kinase 2.
Chen H; Van Duyne R; Zhang N; Kashanchi F; Zeng C
Proteins; 2009 Jan; 74(1):122-32. PubMed ID: 18615713
[TBL] [Abstract][Full Text] [Related]
34. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
Echalier A; Bettayeb K; Ferandin Y; Lozach O; Clément M; Valette A; Liger F; Marquet B; Morris JC; Endicott JA; Joseph B; Meijer L
J Med Chem; 2008 Feb; 51(4):737-51. PubMed ID: 18232649
[TBL] [Abstract][Full Text] [Related]
35. Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations.
Heady L; Fernandez-Serra M; Mancera RL; Joyce S; Venkitaraman AR; Artacho E; Skylaris CK; Ciacchi LC; Payne MC
J Med Chem; 2006 Aug; 49(17):5141-53. PubMed ID: 16913703
[TBL] [Abstract][Full Text] [Related]
36. Crystal structure of a gamma-herpesvirus cyclin-cdk complex.
Card GL; Knowles P; Laman H; Jones N; McDonald NQ
EMBO J; 2000 Jun; 19(12):2877-88. PubMed ID: 10856233
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
38. The transcriptional co-activator PCAF regulates cdk2 activity.
Mateo F; Vidal-Laliena M; Canela N; Zecchin A; Martínez-Balbás M; Agell N; Giacca M; Pujol MJ; Bachs O
Nucleic Acids Res; 2009 Nov; 37(21):7072-84. PubMed ID: 19773423
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for the interaction of the fluorescence probe 8-anilino-1-naphthalene sulfonate (ANS) with the antibiotic target MurA.
Schonbrunn E; Eschenburg S; Luger K; Kabsch W; Amrhein N
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6345-9. PubMed ID: 10823915
[TBL] [Abstract][Full Text] [Related]
40. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
